HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CISATRACURIUM BESYLATE INJECTION safely and effectively. See full prescribing information for CISATRACURIUM BESYLATE INJECTION.
CISATRACURIUM BESYLATE injection, for intravenous use
Initial U.S. Approval: 1995
INDICATIONS AND USAGE
Cisatracurium Besylate Injection is a nondepolarizing neuromuscular blocker indicated:
Limitations of Use:
Cisatracurium Besylate Injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
The most common adverse reactions (0.1% to 0.4%) were bradycardia, hypotension, flushing, bronchospasm, and rash. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Patients with Hemiparesis or Paraparesis: Perform neuromuscular monitoring on non-paretic limb. (8.9)
See 17 for PATIENT COUNSELING INFORMATION.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
cisatracurium besylate Highlights
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.If you cannot use the above website or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at